2022 - Research.com Best Female Scientist Award
Valerie W. Rusch mainly focuses on Lung cancer, Surgery, Adenocarcinoma, Stage and Cancer. Valerie W. Rusch interconnects Carcinoma and Chemotherapy in the investigation of issues within Lung cancer. Her work carried out in the field of Carcinoma brings together such families of science as Retrospective cohort study, Survival analysis and Oncology.
Her Surgery research is multidisciplinary, incorporating elements of Pneumonectomy and Extrapleural Pneumonectomy. Her Adenocarcinoma study incorporates themes from Esophageal cancer, KRAS, Lung, Gefitinib and Esophagus. Her Stage research integrates issues from Lymph node, Mesothelioma, Radiology and Adjuvant therapy.
Her primary areas of investigation include Surgery, Internal medicine, Lung cancer, Oncology and Cancer. Surgery connects with themes related to Pneumonectomy in her study. Her Lung cancer study combines topics in areas such as Stage, Carcinoma, Radiology and Clinical trial.
Her study in the field of Non small cell, non-small cell lung cancer and Lung cancer staging is also linked to topics like In patient. Her study explores the link between Pathology and topics such as Cancer research that cross with problems in Epidermal growth factor receptor. Valerie W. Rusch combines subjects such as Esophagus and KRAS with her study of Adenocarcinoma.
Her primary areas of study are Internal medicine, Oncology, Lung cancer, Surgery and Cancer. Her biological study spans a wide range of topics, including Prospective cohort study, Atezolizumab, Targeted therapy and Chemotherapy. Her Lung cancer research incorporates elements of Neoadjuvant therapy, Clinical trial, Carcinoma, Radiology and Nivolumab.
Valerie W. Rusch studied Surgery and Pneumonectomy that intersect with Comorbidity. Her Cancer study also includes
Her primary areas of investigation include Internal medicine, Oncology, Lung cancer, Cancer and Surgery. Her Oncology study integrates concerns from other disciplines, such as Chemotherapy, Carcinoma, Lung, Stage and Prospective cohort study. Her Lung cancer research includes elements of Neoadjuvant therapy, Nivolumab, Clinical trial and Radiology.
Her Clinical trial research is multidisciplinary, incorporating elements of Adjuvant and Mesothelioma. Her Cancer research is multidisciplinary, incorporating perspectives in Mutation and Cancer research. Her research in Surgery intersects with topics in Metastasectomy, Adverse effect and Primary tumor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
William Pao;Vincent Miller;Maureen Zakowski;Jennifer Doherty.
Proceedings of the National Academy of Sciences of the United States of America (2004)
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
William D Travis;Elisabeth Brambilla;Masayuki Noguchi;Andrew G Nicholson.
Journal of Thoracic Oncology (2011)
Comprehensive molecular profiling of lung adenocarcinoma: The cancer genome atlas research network
Eric A. Collisson;Joshua D. Campbell;Angela N. Brooks;Angela N. Brooks;Alice H. Berger.
The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.
Peter Goldstraw;John Crowley;Kari Chansky;Dorothy J. Giroux.
Journal of Thoracic Oncology (2007)
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.
Andy Trotti;A.Dimitrios Colevas;Ann Setser;Valerie Rusch.
Seminars in Radiation Oncology (2003)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman;Doug Voet;Michael S. Lawrence;Douglas Voet.
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
Peter Goldstraw;Kari Chansky;John Crowley;Ramon Rami-Porta.
Journal of Thoracic Oncology (2016)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean;Cameron Brennan;Jin-Yuan Shih;Gregory Riely.
Proceedings of the National Academy of Sciences of the United States of America (2007)
Incidence of local recurrence and second primary tumors in resected stage I lung cancer
Nael Martini;Manjit S. Bains;Michael E. Burt;Maureen F. Zakowski.
The Journal of Thoracic and Cardiovascular Surgery (1995)
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
Kathy S Albain;R Suzanne Swann;Valerie W Rusch;Andrew T Turrisi.
The Lancet (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: